MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year

MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference.

MIMEDX to Present at TD Cowen 44th Annual Health Care Conference

Amylyx Pharmaceuticals

BeiGene

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.

Get Rich Quick With These 3 Biotech Stocks to Buy Now

MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities

MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing

NEW YORK , Jan. 19, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MiMedx's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MiMedx's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your MiMedx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's possible violations of federal securities laws. On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company's placental-derived tissue product, Axiofill, does not meet the requirements as a.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company's pla.

The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

MiMedx Group said on Friday it had received a warning letter from the U.S. Food and Drug Administration related to the classification of its placental-derived tissue product Axiofill, and its shares fell 7% after the bell.

MiMedx reports US FDA warning letter for Axiofill, shares drop

Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net Sales Growth in the High Teens and Fourth Quarter Adjusted EBITDA Margin of Above 20% MARIETTA, Ga., Dec. 29, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin.

MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook

MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued dividends, were automatically converted into shares of the Company's Common Stock on December 22, 2023, in accordance with the Preferred Stock terms set forth in the Company's Articles of Incorporation. As a result of this conversion, approximately 30 million shares of Common Stock have been added to the Company's share count. The conversion of the shares ends the dividend accrual associated with the Preferred Stock.

MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock

MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV.

MIMEDX to Highlight Published Data at SAWC Fall

MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2023 Earnings Call October 30, 2023 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph H. Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C.

MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript

Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the High Teens MARIETTA, Ga., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the quarter ended September 30, 2023.

MIMEDX Announces Third Quarter 2023 Operating and Financial Results

MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets RK - H.C. Wainwright John Vandermosten - Zacks SCR Operator Good afternoon and thank you for standing by.

MiMedx Group, Inc. (MDXG) Q2 2023 Earnings Call Transcript

Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer Management to Host Conference Call on Tuesday, August 1, 2023, at 5:00 PM ET MARIETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2023, which ended June 30, 2023, including net sales of $81.3 million, net income of $1.2 million and Adjusted EBITDA1 of $14.1 million.

MIMEDX Announces Second Quarter 2023 Operating and Financial Results

MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.

MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1

MARIETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the Eleventh Circuit Court of Appeals affirmed the dismissal of the putative securities class action lawsuit brought against the Company and others in 2019. In the action, the plaintiff claimed that the Company violated federal securities laws. The case was on appeal from the United States District Court for the Northern District of Georgia.

MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case

MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has appointed Doug Rice as the Company's Chief Financial Officer, effective today.

MIMEDX Appoints Doug Rice as Chief Financial Officer

Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbanding Regenerative Medicine Business Unit

MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability

MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2023 Earnings Conference Call May 2, 2023 5:00 PM ET Company Participants Matt Notarianni - Head, IR Joe Capper - CEO Pete Carlson - CFO Conference Call Participants Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.

MiMedx Group, Inc. (MDXG) Q1 2023 Earnings Call Transcript

First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period

News for MiMedx Group Stock (MDXG)